Christopher Krueger

Leidos, Inc. provides scientific, engineering, systems integration and technical services and solutions. It offers solutions and services that leverage the power of data analytics, systems integration, and cyber security across national security, health, and engineering markets. The company was founded by John Robert Beyster in June 1969 and is headquartered in Reston, VA.

Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA.

Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held.

ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA.

CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.

J.E.M. Capital, Inc. is a a shell company, which engages in the identification of a privately held operating company which desires to become a publicly held entity by merging with the firm through a reverse merger or acquisition. The company was founded on September 14, 2011 and is headquartered in Hong Kong.

BioCision LLC operates as a life science research and development company. Its products include cell cryopreservation systems, sample cooling, freezing, snap-freezing, ice-free cooling systems, tube temperature and plate temperature management, support platforms, sample transport, cryostorage boxes, cryogenic vials, ice pans and buckets and other accessories. The firm’s products protect temperature-sensitive therapeutics, biological samples and biomaterials. The company was founded by Brian Schryver and Rolf O. Ehrhardt in 2007 and is headquartered in San Rafael, CA.